US experts urged regulators Wednesday to approve a second new anti-cholesterol drug, a day after recommending they bring to market the first in a new class of medications to lower the risk of heart attack.
Jun 10, 2015
0
11
Federal health advisers on Tuesday recommended approval for a highly-anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with the caveat that more data is needed about its long-term ability to reduce ...
Jun 9, 2015
0
42
Federal health regulators said Monday a highly-anticipated, experimental drug from Amgen significantly lowers bad cholesterol. But officials have questions about who should take the drug and whether to approve it based on ...
Jun 8, 2015
0
3
Federal health regulators said Friday that a highly-anticipated, experimental drug from Sanofi lowers bad cholesterol more than older drugs. But officials have questions about whether to approve the drug based on that measure ...
Jun 5, 2015
0
40
A top US federal research center has suspended some activities after the discovery of serious manufacturing problems and other issues requiring corrective actions, health officials said Thursday.
Jun 5, 2015
0
6
The drug industry's decade-spanning search for a female equivalent to Viagra took a major step forward Thursday, as government experts recommended approval for a pill to boost sexual desire in women.
Jun 4, 2015
0
61
A US advisory panel on Thursday urged regulators to approve a drug nicknamed the "female Viagra" because it could help increase women's sex drive.
Jun 4, 2015
0
4
A drug nicknamed the "female Viagra" because it could help increase women's sex drive, will be discussed for a third time at a meeting of an advisory committee to US regulators Thursday.
Jun 4, 2015
0
5
The makers of a pill intended to boost sexual desire in women will try again this week to persuade regulators that the drug warrants approval after two rejections.
Jun 2, 2015
0
20
Treatment options for chronic hepatitis C, a serious and life-threatening infection, have improved substantially and several new regimens with shorter durations and improved efficacy and safety profiles are now available.
Jun 2, 2015
0
11
